This report aims to estimate the impacts of providing remdesivir as an inpatient treatment for COVID-19 in Canada on health system costs and health outcomes.
The analyses presented in this report were conducted using 2022 data, which represented a year of the pandemic when a large proportion of the population in Canada was infected with COVID-19.
Several drug treatments for COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are approved for use in Canada. This systematic review evaluated the efficacy and safety of remdesivir for the treatment of COVID-19 in hospitalized adult and adolescent patients from settings within the health care systems in Canada or from countries with economies similar to Canada. We also characterized which hospitalized patients are most likely to benefit from treatment with remdesivir.